Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX® Production Platform
Berlin, Germany – May 4, 2023 ProBioGen announces that their proprietary vaccine production cell line AGE1.CR.pIX® has been successfully used to manufacture a viral vector product..
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
Berlin, Germany and Zurich, Switzerland – April 12, 2023 ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of..
ProBioGen Delivers Strong 2022 Performance, Investing for Growth in 2023
Berlin, Germany – March 30, 2023 ProBioGen, the Berlin-based CDMO and technology provider, reported today that revenues for the fiscal year 2022 (FY22) grew 35% vs FY21. In a year..
_fav.png)
ProBioGen’s Growth Strategy Continues Successfully
Julian Collins, Jana Windt and Michiel Stork Join Biopharma Company’s Leadership Team Berlin, Germany – March 2, 2023 ProBioGen has seen significant growth with over 300 employees..
Another Clinical Asset Using ProBioGen's GlymaxX® Technology Begins Phase III
Berlin, Germany – January 26, 2023 ProBioGen today announced that a Novartis clinical candidate using its antibody-dependent cellular cytotoxicity (ADCC) technology, GlymaxX, has..
ProBioGen’s Vaccine Production Cell Line AGE1.CR.pIX® Used for Clinical Production
Berlin, Germany – January 18, 2023 ProBioGen is announcing another important clinical milestone for its proprietary viral vector and vaccine production cell line AGE1.CRpIX®. Our..
ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck® Transposase Technology
Berlin, Germany – January 10, 2023 ProBioGen announced today a new non-exclusive collaboration with Boehringer Ingelheim on ProBioGen's DirectedLuck® transposase technology...
Dr. Simon Bulling Joins ProBioGen as Chief Operating Officer to Drive Next Phase of Operational Growth
Apr 21, 2026
ProBioGen Introduces CMC Navigator™ to Help Biopharma Teams Select the Best CMC Path Forward
Feb 17, 2026
ProBioGen and Zag Bio™ Forge Strategic CMC Partnership to Advance Fc-Fusion Autoimmune Therapy
Jan 6, 2026
ProBioGen and Spica Therapeutics Announce Collaboration on GlymaxX-Enhanced CLD for Spica’s Clinical Development Candidate ST101
Dec 9, 2025
IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa
Oct 10, 2025
%20kooperieren%20im%20Berlin%20Center%20for%20Gene%20und%20Cell%20Therapies%20(BC%20GCT)-2.webp)
ProBioGen to Lead GMP Manufacturing Operations at Berlin Center for Gene and Cell Therapies (BC GCT)
Sep 16, 2025
ProBioGen und das Berlin Institute of Health in der Charité (BIH) kooperieren im Berlin Center for Gene und Cell Therapies (BC GCT)
Sep 16, 2025
ProBioGen Enters Agreement with Polpharma Biologics to Provide High-Performance Cell Line Development Services
May 7, 2025
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Mar 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
